LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). (25th November 2018) - Mok, T S K; Reck, M; Horn, L; Lam, S; Shames, D S; Liu, J; Kabbinavar, F; Lin, W; Sandler, A; Liu, S V